Skip to main content
AAN.com

Abstract

Background: PET studies with N-methyl-[11C]2-(4′:-methylaminophenyl)-6-hydroxybenzothiazole ([11C]PIB) have revealed an increased tracer uptake in several brain regions in Alzheimer disease (AD).
Objective: To employ voxel-based analysis method to identify brain regions with significant increases in [11C]PIB uptake in AD vs healthy control subjects, indicative of increased amyloid accumulation in these regions.
Methods: We studied 17 patients with AD and 11 control subjects with PET using [11C]PIB as tracer. Parametric images were computed by calculating a region-to-cerebellum ratio over 60 to 90 minutes in each voxel. Group differences in [11C]PIB uptake were analyzed with statistical parametric mapping (SPM) and automated region-of-interest (ROI) analysis.
Results: SPM showed increased uptake (p < 0.001) in the frontal, parietal, and lateral temporal cortices as well as in the posterior cingulate and the striatum. No significant differences in uptake were found in the primary sensory and motor cortices, primary visual cortex, thalamus, and medial temporal lobe. These results were supported by automated ROI analysis, with most prominent increases in AD subjects in the frontal cortex ([11C]PIB uptake 163% of the control mean) and posterior cingulate (146%) followed by the parietal (146%) and temporal (145%) cortices and striatum (133%), as well as small increases in the occipital cortex (117%) and thalamus (115%).
Conclusions: Voxel-based analysis revealed widespread distribution of increased [11C]PIB uptake in Alzheimer disease (AD). These findings are in accordance with the distribution and phases of amyloid pathology in AD, previously documented in postmortem studies.

Get full access to this article

View all available purchase options and get full access to this article.

Supplementary Material

File (kemppainen.pdf)
File (kemppainen_67-1575.pdf)

References

1.
Klunk WE, Debnath ML, Pettegrew JW. Development of small molecule probes for the beta-amyloid protein of Alzheimer’s disease. Neurobiol Aging 1994;15:691–698.
2.
Wengenack TM, Curran GL, Poduslo JF. Targeting Alzheimer amyloid plaques in vivo. Nat Biotechnol 2000;18:868–872.
3.
Klunk WE, Wang Y, Huang GF, Debnath ML, Holt DP, Mathis CA. Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci 2001;69:1471–1484.
4.
Agdeppa ED, Kepe V, Liu J, et al. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer’s disease. J Neurosci 2001; 21:RC189.
5.
Zhuang ZP, Kung MP, Hou C, et al. Radioiodinated styrylbenzenes and thioflavins as probes for amyloid aggregates. J Med Chem 2001;44:1905–1914.
6.
Shoghi-Jadid K, Small GW, Agdeppa ED, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 2002;10:24–35.
7.
Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306–319.
8.
Verhoeff NP, Wilson AA, Takeshita S, et al. In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry 2004;12:584–595.
9.
Klunk WE, Wang Y, Huang GF, et al. The binding of 2-(4′:-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci 2003;23:2086–2092.
10.
Price JC, Klunk WE, Lopresti BJ, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 2005;25:1528–1547.
11.
Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 2003;46:2740–2754.
12.
Wilson AA, Garcia A, Chestakova A, Kung HF, Houle S. A rapid one-step radiosynthesis of the β-amyloid radiotracer N-methyl-[11C]2-(4′:-methylaminophenyl)-6-hydroxybenzothiazole ([11C]-6-OH-BTA-1). J Label Comp Radiopharm 2005;47:679–682.
13.
Solbach C, Uebele M, Reischl G, Machulla HJ. Efficient radiosynthesis of carbon-11 labelled uncharged Thioflavin T derivatives using [11C]methyl triflate for beta-amyloid imaging in Alzheimer’s disease with PET. Appl Radiat Isot 2005;62:591–595.
14.
Joachim CL, Morris JH, Selkoe DJ. Diffuse senile plaques occur commonly in the cerebellum in Alzheimer’s disease. Am J Pathol 1989;135:309–319.
15.
Yamaguchi H, Hirai S, Morimatsu M, Shoji M, Ihara Y. A variety of cerebral amyloid deposits in the brains of the Alzheimer-type dementia demonstrated by beta protein immunostaining. Acta Neuropathol (Berl) 1988;76:541–549.
16.
Friston KJ, Holmes AP, Worsley KJ, Poline JB, Frith CD, Franckowiak RSJ. Statistical parametric maps in functional imaging. A general approach. Hum Brain Map 1995;2:189–210.
17.
Meyer JH, Gunn RN, Myers R, Grasby PM. Assessment of spatial normalization of PET ligand images using ligand-specific templates. Neuroimage 1999;9:545–553.
18.
Brett M, Johnsrude IS, Owen AM. The problem of functional localization in the human brain. Nat Rev Neurosci 2002;3:243–249.
19.
Lancaster JL, Woldorff MG, Parsons LM, et al. Automated Talairach Atlas labels for functional brain mapping. Hum Brain Map 2000;10:120–131.
20.
Brück A, Aalto S, Nurmi E, Bergman J, Rinne JO. Cortical 6-[18F]fluoro-l-dopa uptake and frontal cognitive functions in early Parkinson’s disease. Neurobiol Aging 2005;26:891–898.
21.
Lopresti BJ, Klunk WE, Mathis CA, et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 2005;46:1959–1972.
22.
Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82:239–259.
23.
Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002;58:1791–1800.
24.
Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and functional characterization of Alzheimer’s disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005;25:7709–7717.
25.
Matsuda H. Cerebral blood flow and metabolic abnormalities in Alzheimer’s disease. Ann Nucl Med 2001;15:85–92.
26.
Minoshima S, Foster NL, Kuhl DE. Posterior cingulate cortex in Alzheimer’s disease. Lancet 1994;344:895.

Information & Authors

Information

Published In

Neurology®
Volume 67Number 9November 14, 2006
Pages: 1575-1580
PubMed: 16971697

Publication History

Published online: September 13, 2006
Published in print: November 14, 2006

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

N. M. Kemppainen, MD, PhD
From the Turku PET Centre (N.M.K., S.A., K.N., S.H., A.B., V.O., J.O.R.) and Department of Pharmacology and Clinical Research Services Turku (CRST) (M.K., M.S.), University of Turku, Department of Psychology (S.A.), óbo Akademi University, Turku City Hospital (M.V.), Department of Clinical Radiology, Turku University Hospital (R.P.), Turku Imanet Ltd (J.O.R.), Turku, Finland; GE Healthcare Medical Diagnostics (I.A.W.), UK; and Clinical Geriatrics (M.V.), Karolinska Institutet, Stockholm, Sweden.
S. Aalto, MSc
From the Turku PET Centre (N.M.K., S.A., K.N., S.H., A.B., V.O., J.O.R.) and Department of Pharmacology and Clinical Research Services Turku (CRST) (M.K., M.S.), University of Turku, Department of Psychology (S.A.), óbo Akademi University, Turku City Hospital (M.V.), Department of Clinical Radiology, Turku University Hospital (R.P.), Turku Imanet Ltd (J.O.R.), Turku, Finland; GE Healthcare Medical Diagnostics (I.A.W.), UK; and Clinical Geriatrics (M.V.), Karolinska Institutet, Stockholm, Sweden.
I. A. Wilson, PhD
From the Turku PET Centre (N.M.K., S.A., K.N., S.H., A.B., V.O., J.O.R.) and Department of Pharmacology and Clinical Research Services Turku (CRST) (M.K., M.S.), University of Turku, Department of Psychology (S.A.), óbo Akademi University, Turku City Hospital (M.V.), Department of Clinical Radiology, Turku University Hospital (R.P.), Turku Imanet Ltd (J.O.R.), Turku, Finland; GE Healthcare Medical Diagnostics (I.A.W.), UK; and Clinical Geriatrics (M.V.), Karolinska Institutet, Stockholm, Sweden.
K. Någren, PhD
From the Turku PET Centre (N.M.K., S.A., K.N., S.H., A.B., V.O., J.O.R.) and Department of Pharmacology and Clinical Research Services Turku (CRST) (M.K., M.S.), University of Turku, Department of Psychology (S.A.), óbo Akademi University, Turku City Hospital (M.V.), Department of Clinical Radiology, Turku University Hospital (R.P.), Turku Imanet Ltd (J.O.R.), Turku, Finland; GE Healthcare Medical Diagnostics (I.A.W.), UK; and Clinical Geriatrics (M.V.), Karolinska Institutet, Stockholm, Sweden.
S. Helin, MSc
From the Turku PET Centre (N.M.K., S.A., K.N., S.H., A.B., V.O., J.O.R.) and Department of Pharmacology and Clinical Research Services Turku (CRST) (M.K., M.S.), University of Turku, Department of Psychology (S.A.), óbo Akademi University, Turku City Hospital (M.V.), Department of Clinical Radiology, Turku University Hospital (R.P.), Turku Imanet Ltd (J.O.R.), Turku, Finland; GE Healthcare Medical Diagnostics (I.A.W.), UK; and Clinical Geriatrics (M.V.), Karolinska Institutet, Stockholm, Sweden.
A. Brück, MD, PhD
From the Turku PET Centre (N.M.K., S.A., K.N., S.H., A.B., V.O., J.O.R.) and Department of Pharmacology and Clinical Research Services Turku (CRST) (M.K., M.S.), University of Turku, Department of Psychology (S.A.), óbo Akademi University, Turku City Hospital (M.V.), Department of Clinical Radiology, Turku University Hospital (R.P.), Turku Imanet Ltd (J.O.R.), Turku, Finland; GE Healthcare Medical Diagnostics (I.A.W.), UK; and Clinical Geriatrics (M.V.), Karolinska Institutet, Stockholm, Sweden.
V. Oikonen, MSc
From the Turku PET Centre (N.M.K., S.A., K.N., S.H., A.B., V.O., J.O.R.) and Department of Pharmacology and Clinical Research Services Turku (CRST) (M.K., M.S.), University of Turku, Department of Psychology (S.A.), óbo Akademi University, Turku City Hospital (M.V.), Department of Clinical Radiology, Turku University Hospital (R.P.), Turku Imanet Ltd (J.O.R.), Turku, Finland; GE Healthcare Medical Diagnostics (I.A.W.), UK; and Clinical Geriatrics (M.V.), Karolinska Institutet, Stockholm, Sweden.
M. Kailajärvi, MD, PhD
From the Turku PET Centre (N.M.K., S.A., K.N., S.H., A.B., V.O., J.O.R.) and Department of Pharmacology and Clinical Research Services Turku (CRST) (M.K., M.S.), University of Turku, Department of Psychology (S.A.), óbo Akademi University, Turku City Hospital (M.V.), Department of Clinical Radiology, Turku University Hospital (R.P.), Turku Imanet Ltd (J.O.R.), Turku, Finland; GE Healthcare Medical Diagnostics (I.A.W.), UK; and Clinical Geriatrics (M.V.), Karolinska Institutet, Stockholm, Sweden.
M. Scheinin, MD, PhD
From the Turku PET Centre (N.M.K., S.A., K.N., S.H., A.B., V.O., J.O.R.) and Department of Pharmacology and Clinical Research Services Turku (CRST) (M.K., M.S.), University of Turku, Department of Psychology (S.A.), óbo Akademi University, Turku City Hospital (M.V.), Department of Clinical Radiology, Turku University Hospital (R.P.), Turku Imanet Ltd (J.O.R.), Turku, Finland; GE Healthcare Medical Diagnostics (I.A.W.), UK; and Clinical Geriatrics (M.V.), Karolinska Institutet, Stockholm, Sweden.
M. Viitanen, MD, PhD
From the Turku PET Centre (N.M.K., S.A., K.N., S.H., A.B., V.O., J.O.R.) and Department of Pharmacology and Clinical Research Services Turku (CRST) (M.K., M.S.), University of Turku, Department of Psychology (S.A.), óbo Akademi University, Turku City Hospital (M.V.), Department of Clinical Radiology, Turku University Hospital (R.P.), Turku Imanet Ltd (J.O.R.), Turku, Finland; GE Healthcare Medical Diagnostics (I.A.W.), UK; and Clinical Geriatrics (M.V.), Karolinska Institutet, Stockholm, Sweden.
R. Parkkola, MD, PhD
From the Turku PET Centre (N.M.K., S.A., K.N., S.H., A.B., V.O., J.O.R.) and Department of Pharmacology and Clinical Research Services Turku (CRST) (M.K., M.S.), University of Turku, Department of Psychology (S.A.), óbo Akademi University, Turku City Hospital (M.V.), Department of Clinical Radiology, Turku University Hospital (R.P.), Turku Imanet Ltd (J.O.R.), Turku, Finland; GE Healthcare Medical Diagnostics (I.A.W.), UK; and Clinical Geriatrics (M.V.), Karolinska Institutet, Stockholm, Sweden.
J. O. Rinne, MD, PhD
From the Turku PET Centre (N.M.K., S.A., K.N., S.H., A.B., V.O., J.O.R.) and Department of Pharmacology and Clinical Research Services Turku (CRST) (M.K., M.S.), University of Turku, Department of Psychology (S.A.), óbo Akademi University, Turku City Hospital (M.V.), Department of Clinical Radiology, Turku University Hospital (R.P.), Turku Imanet Ltd (J.O.R.), Turku, Finland; GE Healthcare Medical Diagnostics (I.A.W.), UK; and Clinical Geriatrics (M.V.), Karolinska Institutet, Stockholm, Sweden.

Notes

Address correspondence and reprint requests to Dr Rinne, Turku PET Centre, University of Turku, P.O. Box 52, FIN-20521 Turku, Finland; e-mail: [email protected]

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. The Role of Brain Integrity in the Association between Occupational Complexity and Cognitive Performance in Subjects with Increased Risk of Dementia, Gerontology, 69, 8, (972-985), (2023).https://doi.org/10.1159/000530688
    Crossref
  2. Research Applications of PET Imaging in Neuroscience, PET/MR: Functional and Molecular Imaging of Neurological Diseases and Neurosciences, (13-45), (2023).https://doi.org/10.1007/978-981-19-9902-4_2
    Crossref
  3. Spatial Distribution and Hierarchical Clustering of β-Amyloid and Glucose Metabolism in Alzheimer’s Disease, Frontiers in Aging Neuroscience, 14, (2022).https://doi.org/10.3389/fnagi.2022.788567
    Crossref
  4. Regional amyloid correlates of cognitive performance in ageing and mild cognitive impairment, Brain Communications, 4, 1, (2022).https://doi.org/10.1093/braincomms/fcac016
    Crossref
  5. Alzheimer's disease, Pathy's Principles and Practice of Geriatric Medicine, (794-807), (2022).https://doi.org/10.1002/9781119484288.ch63
    Crossref
  6. Effects of White Matter Hyperintensities on Verbal Fluency in Healthy Older Adults and MCI/AD, Frontiers in Aging Neuroscience, 13, (2021).https://doi.org/10.3389/fnagi.2021.614809
    Crossref
  7. Investigating the Spatial Associations Between Amyloid-β Deposition, Grey Matter Volume, and Neuroinflammation in Alzheimer’s Disease, Journal of Alzheimer's Disease, 80, 1, (113-132), (2021).https://doi.org/10.3233/JAD-200840
    Crossref
  8. Change in CAIDE Dementia Risk Score and Neuroimaging Biomarkers During a 2-Year Multidomain Lifestyle Randomized Controlled Trial: Results of a Post-Hoc Subgroup Analysis, The Journals of Gerontology: Series A, 76, 8, (1407-1414), (2021).https://doi.org/10.1093/gerona/glab130
    Crossref
  9. Episodic memory and cortical amyloid pathology: PET study in cognitively discordant twin pairs, Neurobiology of Aging, 108, (122-132), (2021).https://doi.org/10.1016/j.neurobiolaging.2021.08.016
    Crossref
  10. Spatial Patterns of Amyloid Deposition in Patients with Chronic Focal or Diffuse Traumatic Brain Injury Using 18F-FPYBF-2 PET

    ,
    Neuropsychiatric Disease and Treatment, Volume 16, (2719-2732), (2020).https://doi.org/10.2147/NDT.S268504
    Crossref
  11. See more
Loading...

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share